What You Should Know:
- PreciseDx, a pioneering company in oncology diagnostics utilizing artificial intelligence (AI) raises $20.7M in Series B funding led by Eventide Asset Management with participation from Labcorp, Quest Diagnostics, GenHenn Capital Venture, and existing investors. This brings the company's total funding to date to $31.5M.
- The new funding will enable PreciseDx to accelerate its growth and expand its operations. The company plans to invest in talent
Read More
Cancer Detection
Color Health Expands Cancer Screening with SkinIO and Bexa Partnerships
What You Should Know:
- Color Health, a leader in comprehensive cancer care, announced today that it is partnering with SkinIO and Bexa to integrate their innovative solutions for skin and breast cancer screening into its Virtual Cancer Clinic.
- The collaboration aims to significantly increase cancer screening and detection rates, making early diagnosis more accessible for employers and individuals.
Bringing Cutting-Edge Screening to the Workplace and Beyond
SkinIO: This
Read More
PathAI Unveils New AI-Powered Pathology Tools for Cancer Research
What You Should Know:
- PathAI, a global leader in AI-powered pathology, unveiled two novel AI products, PathExplore™ Immuno-Oncology Profiling (IOP) and IHC Explore1™ to empower cancer drug developers and clinical researchers with AI-powered insights.
- The product pairing provides unprecedented single-cell and spatial resolution of
Read More
AccessHope Secures $33M to Expand Cancer Care Expertise
What You Should Know:
- AccessHope, a company revolutionizing how cancer patients receive cutting-edge treatment plans secures $33M in a Series B funding round led by City of Hope, a prominent cancer research and treatment organization.
- The company plans to use the investment to fuel AccessHope's next phase of growth as a standalone company.
New CEO Bradley Kreick Takes the Helm
To spearhead this growth trajectory, AccessHope has appointed seasoned healthcare
Read More
Culmination Bio, BillionToOne Partner to Validate Cancer Diagnostics
What You Should Know:
Culmination Bio, a data and technology company combining clinical and biospecimen data, announced a partnership with BillionToOne, Inc., a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all.Culmination Bio and BillionToOne are working together to leverage their respective strengths in order to facilitate the development and validation of robust and impactful oncology
Read More
Lunit Expands AI-powered Cancer Screening Solution to France and Portugal
What You Should Know:
- Lunit (KRX:328130.KQ), a provider of AI-powered cancer diagnostics and therapeutics solutions, announced today two significant commercial agreements that mark its continued European expansion.
- These strategic deals will bring Lunit's AI-powered cancer screening solution to healthcare providers in France and Portugal, aiding in the fight against cancer.
TeleDiag and Lunit Partner to Improve Lung Cancer Detection in France
Lunit has partnered with TeleDiag,
Read More
Veracyte Acquires C2i Genomics for $70M, Expanding into Minimal Residual Disease Detection
What You Should Know:
- Veracyte, Inc. (Nasdaq: VCYT), a cancer diagnostics company acquires C2i Genomics, Inc., a pioneer in minimal residual disease (MRD) detection.
- Under the terms of the agreement, Veracyte will pay $70 million in Veracyte shares at closing, and up to an additional $25 million based on the achievement of future performance milestones over the next two years, payable in Veracyte shares or cash at Veracyte’s election.
- This strategic move positions Veracyte to
Read More
Absci and AstraZeneca Sign $247M Partnership for AI-Powered Drug Discovery to Fight Cancer
What You Should Know:
- Absci Corporation (ABSI), a pioneer in using generative AI to discover antibodies, and AstraZeneca, a global biopharmaceutical leader, announced a collaboration today to develop an AI-designed antibody for cancer.
- This partnership combines Absci's cutting-edge Integrated Drug Creation™ platform with AstraZeneca's oncology expertise, aiming to accelerate the discovery of a potential new cancer treatment.
Absci's AI Engine Takes the Lead
Absci will leverage
Read More
First CPT Code for AI Prostate Cancer Imaging Issued for Avenda Health
What You Should Know:
- Avenda Health's AI mapping tool for prostate cancer, Unfold AI™, has received significant recognition by obtaining a new Category III CPT code in the 2024 Current Procedural Terminology (CPT) code set, signifying its status as a cutting-edge medical technology.
- The new Category III CPT code, X237T, outlines the tool's capabilities, describing it as a non-invasive prostate cancer estimation map that is derived from an augmented analysis of image-guided fusion
Read More
C2i Genomics, Riken Genesis Expands AI-Powered Whole-Genome MRD Cancer Detection Across Japan
What You Should Know:
- C2i Genomics, a cancer intelligence company, today announced a collaboration with Riken Genesis Co., Ltd. (RG), a company specializing in providing the service of personalized medicine based on contract analysis of next-generation sequencing and exomes. The two companies have entered a collaboration agreement to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.
- Under this agreement, RG will work with C2i Genomics to commercialize
Read More
